Gene test could personalize cancer drug dosing

NCT ID NCT06489041

Recruiting now Knowledge-focused Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a broad genetic test (microarray PGx) can find more drug-gene interactions than the standard single-gene test in 120 adults with cancer who are about to receive chemotherapy. The goal is to see if this extra information could help doctors adjust drug doses to reduce side effects. Participants will give a blood or saliva sample for testing, and researchers will count how many potentially actionable results are found.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer digestive system cancer digestive system neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER GASTROINTESTINAL CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Atrium Health Levine Cancer
RECRUITING

Charlotte, North Carolina, 28204, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••